BTL-785-7 Treatment for Wrinkles

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Skin and Allergy Center, Spring Hill, TN
Wrinkles
BTL-785-7 Treatment - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This study will evaluate the clinical safety and the performance of the BTL-785F system equipped with the BTL-785-7 applicator for non-invasive treatment of facial wrinkles.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: 4 months

4 months
Evaluation of skin quality and aesthetic changes of the treated areas after the therapies
Evaluation of skin quality and aesthetic improvement of the treated areas after the therapies
Noninvasive Treatment Of Wrinkles
Subject Satisfaction
Therapy Comfort

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

BTL-785-7 Treatment
1 of 1
Experimental Treatment

22 Total Participants · 1 Treatment Group

Primary Treatment: BTL-785-7 Treatment · No Placebo Group · N/A

BTL-785-7 Treatment
Device
Experimental Group · 1 Intervention: BTL-785-7 Treatment · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 4 months
Closest Location: Skin and Allergy Center · Spring Hill, TN
N/AFirst Recorded Clinical Trial
1 TrialsResearching Wrinkles
0 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.